The European Commission has signed a joint procurement contract with pharmaceutical company Gilead for the supply of up to 500 000 treatment courses of Veklury, the brand name for Remdesivir, and the opportunity to increase supply beyond the 500,000 treatment courses, the Commission said on October 8.
The framework contract will cover all EU member states and the countries of the Western Balkans.
There are 36 signatories of the Joint Procurement Agreement participating in this joint procurement, including all EU countries, the EEA countries of Norway and Iceland*, the UK, as well as six candidate countries and potential candidates (Albania, the Republic of North Macedonia, Montenegro, Serbia, Kosovo** and Bosnia and Herzegovina). All participating countries can now place their orders to procure Veklury directly. Veklury is at this stage the only medicine with a conditional marketing authorisation in the EU for the treatment of COVID-19 patients needing oxygen supply, the statement says.
All participating countries can now place their orders to procure Veklury directly. Veklury is at this stage the only medicine with a conditional marketing authorisation in the EU for the treatment of Covid-19 patients.
The signing of this joint procurement framework contract follows the European Commission’s contract with Gilead to secure 33 380 treatment courses of Veklury that have been distributed across the EU and the UK since August.
Чуй новините
Подкаст
